Journal: Annals of Cardiothoracic Surgery

Article Title: A series of four transcatheter aortic valve replacement in failed Perceval valves

doi: 10.21037/acs-2020-surd-20

Figure Lengend Snippet: Case series and case reports of TAVR procedures in failed sutureless and rapid deployment valves

Article Snippet: Belluschi I, et al. 2020, ( 7 ) , Perceval , AS/AR , CoreValve Evolut R.

Techniques:

Journal: Annals of Cardiothoracic Surgery

Article Title: A series of four transcatheter aortic valve replacement in failed Perceval valves

doi: 10.21037/acs-2020-surd-20

Figure Lengend Snippet: A 29 mm Evolut R is placed into a failed Perceval size L valve.

Article Snippet: Belluschi I, et al. 2020, ( 7 ) , Perceval , AS/AR , CoreValve Evolut R.

Techniques:

Journal: Annals of Cardiothoracic Surgery

Article Title: A series of four transcatheter aortic valve replacement in failed Perceval valves

doi: 10.21037/acs-2020-surd-20

Figure Lengend Snippet: Case summaries

Article Snippet: Belluschi I, et al. 2020, ( 7 ) , Perceval , AS/AR , CoreValve Evolut R.

Techniques:

Journal: JTCVS Open

Article Title: Inflammatory immune response in recipients of transcatheter aortic valves

doi: 10.1016/j.xjon.2021.02.012

Figure Lengend Snippet: Implanted medical devices for transcatheter aortic valve implantation and MitraClip (Abbott Laboratories, Abbott Park, Ill)

Article Snippet: Medtronic, CoreValve Evolut PRO transcatheter aortic valve , 4 , Porcine.

Techniques:

Journal: JTCVS Open

Article Title: Inflammatory immune response in recipients of transcatheter aortic valves

doi: 10.1016/j.xjon.2021.02.012

Figure Lengend Snippet: Serum concentrations of galactose-alpha-1,3-galactose (α-Gal)–specific antibodies in transcatheter aortic valve replacement (TAVI) and MitraClip (Abbott Laboratories, Abbott Park, Ill) recipients

Article Snippet: Medtronic, CoreValve Evolut PRO transcatheter aortic valve , 4 , Porcine.

Techniques:

Journal: JTCVS Open

Article Title: Inflammatory immune response in recipients of transcatheter aortic valves

doi: 10.1016/j.xjon.2021.02.012

Figure Lengend Snippet: Significantly increased serum concentration of complement factor 3a (C3a), citrullinated H3 (CitH3), and soluble suppression of tumorigenicity-2 (sST2) 3 months after transcatheter aortic valve implantation (TAVI) compared with baseline levels. A, Three months after TAVI, C3a serum concentrations were significantly elevated compared to baseline levels. B, C3a serum concentrations did not increase 3 months after MitraClip (Abbott Laboratories, Abbott Park, Ill). C and D, Three months after TAVI and MitraClip, CitH3 serum concentrations were significantly upregulated compared with baseline levels. E and F, In TAVI patients, but not MitraClip patients, sST2 serum concentrations were significantly higher 3 months after intervention. For statistical analyses of serum concentrations between baseline levels and 3 months after TAVI or MitraClip the Wilcoxon matched-pairs signed-rank test was used.

Article Snippet: Medtronic, CoreValve Evolut PRO transcatheter aortic valve , 4 , Porcine.

Techniques: Concentration Assay

Journal: Journal of Thoracic Disease

Article Title: Current issues in transcatheter aortic valve replacement

doi: 10.21037/jtd.2020.01.10

Figure Lengend Snippet: TAVR-currently available FDA and CE-marked prostheses. (A) Edwards–Sapien 3 copyright 2019; (B) Abbott Portico copyright 2019; (C) Boston Scientific ACURATE neo copyright 2019; (D) Medtronic Evolut R copyright 2019.

Article Snippet: In Evolut Low Risk Trial (CoreValve, Evolut R, or Evolut PRO self-expanding valve) 30-day and 2-year disabling stroke rates with TAVR vs. SAVR were 0.5% vs. 1.7% (difference, −1.2 percentage points; 95% credible interval −2.4 to −0.2) and 1.1% vs. 3.5% (difference, −2.3; −4.8 to −0.4) ( 31 ).

Techniques:

Journal: Journal of Thoracic Disease

Article Title: Current issues in transcatheter aortic valve replacement

doi: 10.21037/jtd.2020.01.10

Figure Lengend Snippet: Major randomized clinical trials for transcatheter aortic valve replacement (TAVR)

Article Snippet: In Evolut Low Risk Trial (CoreValve, Evolut R, or Evolut PRO self-expanding valve) 30-day and 2-year disabling stroke rates with TAVR vs. SAVR were 0.5% vs. 1.7% (difference, −1.2 percentage points; 95% credible interval −2.4 to −0.2) and 1.1% vs. 3.5% (difference, −2.3; −4.8 to −0.4) ( 31 ).

Techniques: Clinical Proteomics

Journal: US Cardiology Review

Article Title: Transcatheter Aortic Valve Replacement Optimization Strategies: Cusp Overlap, Commissural Alignment, Sizing, and Positioning

doi: 10.15420/usc.2021.24

Figure Lengend Snippet: Flush Port Orientation and Impact of Initial ‘Hat’ Marker Orientation in Evolut Deployment

Article Snippet: A significant decrease in the incidence of PPMI with the use of new-generation THVs (4.7% versus 7.4%; p=0.017), mainly related to a reduced PPMI rate with the Evolut R/Pro versus CoreValve (3.7% versus 9.0%; p=0.002) was noted.

Techniques: Marker